TARS
Tarsus Pharmaceuticals, Inc.Healthcare · $3.6B market cap
Verdict
We can't put a fair value on TARS right now. It has lost money in each of its last 3 years, and our valuation needs recent profits to project from.
Business quality
1 of 5 clear the 10% bar. What are the Big Five?
Follow TARS
Track it on your watchlist and see the full analysis. Free.
Create a free accountInsider activity
Since Sep 1, 2026: no open-market purchases and 11 sales worth $4.2M. Why purchases matter
Sales
Neervannan Seshadri
Chief Operating Officer · 2026-09-04
Sold
$388K
Lin Elizabeth Yeu
Chief Medical Officer · 2026-09-04
Sold
$143K
Lin Elizabeth Yeu
Chief Medical Officer · 2026-09-04
Sold
$135K
Lin Elizabeth Yeu
Chief Medical Officer · 2026-09-04
Sold
$485K
Lin Elizabeth Yeu
Chief Medical Officer · 2026-09-04
Sold
$458K
Show all 11 salesShow fewer
Azamian Bobak R.
President/CEO and Board Chair · 2026-09-04
Sold
$265K
Azamian Bobak R.
President/CEO and Board Chair · 2026-09-04
Sold
$641K
Azamian Bobak R.
President/CEO and Board Chair · 2026-09-02
Sold
$801K
Lin Elizabeth Yeu
Chief Medical Officer · 2026-09-02
Sold
$127K
Lin Elizabeth Yeu
Chief Medical Officer · 2026-09-02
Sold
$431K
Lin Elizabeth Yeu
Chief Medical Officer · 2026-09-01
Sold
$340K
About Tarsus Pharmaceuticals, Inc.
Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to advancing and commercializing innovative therapies, primarily focusing on ocular conditions. Its leading investigational drug, TP-03, a novel treatment currently in Phase III trials, is being developed to address blepharitis specifically caused by Demodex mite infestations, as well as meibomian gland disease. Beyond this, Tarsus is…
Biotechnology
Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works